Press release - 17/06/2020 CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Waiting for a SARS-CoV-2 vaccine Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
Press release - 26/03/2019 EUR 3 million in series A for the growth and development of Cytena GmbH The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eur-3-million-in-series-a-for-the-growth-and-development-of-cytena-gmbh
Expert interview - 17/10/2018 Biologicals are becoming increasingly important to Boehringer Ingelheim Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
Industry report 2018 - 27/09/2018 The healthcare industry – the innovation driver of the 21st century: opportunities and challenges BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-healthcare-industry-the-innovation-driver-of-the-21st-century
Press release - 27/08/2018 Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-tar
Article - 02/06/2017 SÜDPACK: a great example of biotech as a cross-sectoral technology SÜDPACK Verpackungen is a qualified supplier of plastic films to the biopharmaceutical industry. The company is the leading European manufacturer of packaging products for the food industry and also offers its expertise to the biopharmaceutical industry. In 2011, SÜDPACK created an exclusive cooperation partnership with Sartorius Stedim Biotech, a global technology provider for the pharmaceutical biotech industry, which has now been extended…https://www.gesundheitsindustrie-bw.de/en/article/news/suedpack-a-great-example-of-biotech-as-a-cross-sectoral-technology
Article - 24/05/2017 Ralf Reski: from moss to humans Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…https://www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
Article - 23/02/2017 Rentschler places formulation on biopharmaceuticals production agenda with LEUKOCARE alliance On February 2, 2017, Rentschler Biotechnologie and LEUKOCARE announced a strategic alliance in which LEUKOCARE will become the exclusive formulation developer for the Laupheim-based contract manufacturer. Rentschler will acquire a 10% stake in LEUKOCARE, a biotech company established in 2003 and headquartered in Martinsried. On behalf of BIOPRO, Walter Pytlik spoke with the two CEOs, Rentschler’s Dr. Frank Mathias and LEUKOCARE’s Michael Scholl…https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-places-formulation-on-biopharmaceuticals-production-agenda-with-leukocare-alliance
Article - 16/06/2016 Microfluidic biofermenter mimics plant tissue It is estimated that as many as one million secondary plant metabolites can be used as medical agents. Plants produce these compounds to aid their growth and development as well as to discourage herbivores from eating them. However, it is still very difficult, or even impossible, to produce secondary plant metabolites industrially. Researchers from the Karlsruhe Institute of Technology (KIT) are now developing a microfluidic bioreactor to make…https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-biofermenter-mimics-plant-tissue
Article - 25/01/2016 And yet another biological from Biberach Boehringer Ingelheim is an important contract manufacturer of biopharmaceuticals that also produces proprietary drugs. We spoke with Dr. Joanne van Ryn, a Canadian pharmacologist who has been doing research at Boehringer Ingelheim’s company site in Biberach for over 20 years. Her research focuses on thrombosis, haemostasis and coagulation. She is involved in the scientific monitoring of dabigatran (Pradaxa), an oral anticoagulant that, in 2008,…https://www.gesundheitsindustrie-bw.de/en/article/news/and-yet-another-biological-from-biberach
Press release - 16/11/2015 The Baden-Württemberg healthcare industry – a strong economic power (Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany. https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-baden-wuerttemberg-healthcare-industry-a-strong-economic-power
Article - 02/02/2015 Rentschler Biotechnologie invests in new production plant The Laupheim-based contract manufacturer Rentschler Biotechnologie GmbH is greatly expanding its production capacities. The company is investing €24 million in the construction of two 3,000 litre stainless steel bioreactors, which should be operational in early 2017 and will more than double the production capacities for cell culture-derived proteins. Rentschler also announced recently that it was adding a new 2,000 litre single-use bioreactor…https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-biotechnologie-invests-in-new-production-plant
Guest article - 31/01/2014 Experience report: internship at Boehringer Ingelheim in Shanghai A scholarship from the Baden-Württemberg Ministry of Science, Research and the Arts enabled Henrik Baran to do an internship at Boehringer Ingelheim Pharma GmbH and Co. KG in Shanghai. From March to August 2013, Henrik worked in the company's Global Biopharma Engineering & Technology department where he was involved in cleanroom planning. He was also project coordinator in charge of redeveloping company premises. Here he summarises his…https://www.gesundheitsindustrie-bw.de/en/article/news/experience-report-internship-at-boehringer-ingelheim-in-shanghai
Article - 06/05/2013 HeLa, a human bauplan in the Petri dish Scientists from EMBL have recently sequenced the genome of HeLa cells, which are the world’s most commonly used human cell line. They found that the HeLa genome and that of normal human cells reveal striking differences, caused by chromothripsis and other aberrations. Some evolutionary researchers believe that HeLa cells are developing a new human bauplan as they adapt to cultivation in the Petri dish. https://www.gesundheitsindustrie-bw.de/en/article/news/hela-a-human-bauplan-in-the-petri-dish
Press release - 16/10/2012 Merck Serono Launches € 1 Million Research Grant for Multiple Sclerosis Innovation Merck Serono, a division of Merck, Darmstadt, Germany, announced on 10th Oktober 2012 during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress in Lyon, France, that the company has initiated a new global research award to improve understanding of multiple sclerosis for the ultimate benefit of patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/merck-serono-launches-1-million-research-grant-for-multiple-sclerosis-innovation
Article - 24/10/2011 "Boehringer Ingelheim Ulm University Biocenter" established A festive atmosphere in the life sciences research building on the Ulm University Campus: on Wednesday 19th October, Ulm University and Boehringer Ingelheim signed a research cooperation agreement. The cooperation between academia and industry is also being supported by the Baden-Württemberg government. The new alliance is called “Boehringer Ingelheim Ulm University Biocenter” (BIU) and the funding volume is around 4.5 million euros for an…https://www.gesundheitsindustrie-bw.de/en/article/news/boehringer-ingelheim-ulm-university-biocenter-established
Dossier - 05/10/2011 Biosimilars: follow-on biologics of innovator biopharmaceutical products As blockbuster biopharmaceuticals go off patent, biosimilars are increasingly competing with them for a market share. However, the production of biosimilars is rather complex and costly. The approval of biosimilars is also subject to many hurdles. Their introduction to the very expensive biopharmaceuticals market is often associated with marginal price reductions.https://www.gesundheitsindustrie-bw.de/en/article/dossier/biosimilars-follow-on-biologics-of-innovator-biopharmaceutical-products
Article - 20/09/2011 Expansion and concentration in the biosimilars market Europe is the leader in the global biosimilars business. The prospects are excellent as the patents of many innovator biopharmaceuticals, including therapeutic antibodies, have reached or are about to reach patent expiry. The profitable, though difficult biosimilars market, is increasingly dominated by a handful of financially strong companies. https://www.gesundheitsindustrie-bw.de/en/article/news/expansion-and-concentration-in-the-biosimilars-market
Press release - 26/01/2011 Boehringer Ingelheim to Purchase Amgen’s Fremont (USA) Facility Amgen Inc. and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen’s rights in substantially all assets at Amgen’s Fremont California development and manufacturing facility.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-to-purchase-amgen-s-fremont-usa-facility
Article - 10/01/2011 Review: What does the cell factory of the future look like? A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production. https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
Article - 29/04/2010 The biopharmaceutical industry remained stable in times of crisis The German biopharmaceutical industry has come through 2009 without experiencing too many major slumps. The roaring growth of the biopharmaceutical industry in previous years has been replaced by more moderate growth. This is the result published by the 4th Medical Biotechnology report in 2010 compiled on behalf of the biotech interest group of the vfa bio Association of Research-Oriented Pharmaceutical Companies by the Boston Consulting Group. https://www.gesundheitsindustrie-bw.de/en/article/news/the-biopharmaceutical-industry-remained-stable-in-times-of-crisis
Press release - 18/02/2010 Boehringer Ingelheim acquires patents for antibody production According to a recent announcement by the Bavarian patent exploitation agency of universities and higher education institutions, the pharmaceutical company Boehringer Ingelheim has acquired the rights for a therapeutic antibody development and manufacturing process. https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-acquires-patents-for-antibody-production
Press release - 28/01/2010 Kenta and Rentschler to develop antibodies against hospital-acquired infections The young Swiss company Kenta Biotech will work with the Laupheim-based contract manufacturer Rentschler to develop a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).https://www.gesundheitsindustrie-bw.de/en/article/press-release/kenta-and-rentschler-to-develop-antibodies-against-hospital-acquired-infections
Press release - 03/12/2009 Vetter to open new facility in suburban Chicago On 1st December 2009, the Ravensburg-based contract manufacturer Vetter dedicated its new production facility which will focus on early clinical projects. At the new site in Chicago, Vetter Development Services USA, Inc. will fill very small quantities of product required for pre-clinical through Phase IIb projects. Phase III projects and commercial large-scale production will in future be conducted by the company’s German facilities in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-to-open-new-facility-in-suburban-chicago